Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 9262624
• 负责人: DAN THEODORESCU
• 金额: $ 19.78万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-06 至 2017-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9262624
• 关键词: Animals; Cancer Center; Cancer Center Support Grant; Cancer Control; Catchment Area; Cellular biology; Clinical; Clinical Research; Clinical Sciences; Colorado; Communities; Comprehensive Cancer Center; Development; Developmental Therapeutics Program; Diagnosis; Epidermal Growth Factor Receptor; Funding; Gap Junctions; Grant; Growth; Head Cancer; Health; Health system; Hormones; Hospitals; Human; Image; Institutes; Institution; Investments; Lead; Malignant Neoplasms; Malignant neoplasm of lung; Marshal; Medical center; Medicine; Mission; Morbidity - disease rate; Neck Cancer; Neoplasm Metastasis; Newly Diagnosed; Pathology; Patients; Pediatric Hospitals; Peer Review; Physicians; Population; Prevention; Prevention approach; Program Development; Publications; Request for Applications; Research; Research Personnel; Research Project Grants; Resource Development; Resource Sharing; Resources; Role; Scientist; Seeds; Strategic Planning; Structure; Therapeutic Trials; Therapy Clinical Trials; Training; Translational Research; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Vision; Wyoming; anticancer research; base; biomarker development; cancer care; cancer cell; cancer prevention; cancer stem cell; cancer therapy; cost; drug development; fighting; follower of religion Jewish; health disparity; improved; innovation; medical schools; member; molecular oncology; mortality; next generation; outreach program; personalized care; personalized medicine; prevent; programs; research facility; survivorship; tumor microenvironment

DESCRIPTION (provided by applicant): The University of Colorado Comprehensive Cancer Center (UCCC) is the only NCl-designated Cancer Center in Colorado serving a primary catchment area of Colorado and Wyoming with a population of about 5.5 million. The mission of the UCCC is to discover, develop, and deliver breakthroughs in the diagnosis, treatment, and prevention of cancer with the underlying theme of personalized care woven throughout the enterprise. Structured as a matrix center within the Univ. of Colorado School of Medicine, the UCCC is an NCI recognized consortium encompassing Univ. of Colorado Boulder, Colorado State University, National Jewish Health, Univ. of Colorado Hospital, the Children's Hospital, Denver Health System, Kaiser Permanente of Colorado and the Denver Veterans Administration Medical Center. The consortium institutions have made commitments to cancer medicine of approximately $101 million since 2005. There are 248 full members (nearly all NIH funded cancer researchers in the state of Colorado) who participate in six research programs including: Cancer Cell Biology; Molecular Oncology; Developmental Therapeutics; Hormone-Related Malignancies; Lung, Head & Neck Cancer, and Cancer Prevention and Control. During the past five years, peer-reviewed cancer-related funding reached $102 million and 3,181 publications (35% collaborative) were produced. Our innovation in research is exemplified by our members' lead roles in a lung cancer SPORE, LIVESTRONG Center of Excellence, biomarker development (ALK rearrangement, EGFR) for individualized therapy by our Pathology Shared Resource and development of a top Animal Cancer Center. Annual accrual to therapeutic trials increased from 595 to 1,044 which represent 27% of newly diagnosed patients. Research is supported by 13 Shared Resources located across the consortium and accessible to all UCCC members. These resources leverage NIH investments in our Colorado Clinical and Translational Science Institute (CCTSI) to provide cost efficiencies by avoiding duplication and enhancing critical mass. Development activities focused on strategic recruitments and pilot and seed grant programs have led to a return on investment of $11 million in direct cancer research grant funding. During the next five years, our Strategic Plan includes development of programs in Metastasis and Tumor Microenvironment, Cancer Stem Cells, Survivorship and Health Disparities and a Human Research Imaging Shared Resource which will cross species and enhance our drug development pipeline and personalized therapy clinical trials. Additional clinical and research facilities in construction, will allow us to mainain our upward research and clinical growth trajectory.

描述（由申请人提供）：科罗拉多大学综合癌症中心（UCCC）是科罗拉多州唯一的NCL指定的癌症中心，为科罗拉多州的主要集水区提供服务，怀俄明州人口约为550万。 UCCC的使命是在整个企业中都具有个性化护理的基本主题来发现，发展和提供诊断，治疗和预防癌症的突破。结构为大学内的基质中心。 UCCC是科罗拉多州医学院的，是NCI公认的联盟，包括大学。科罗拉多州立大学科罗拉多博尔德，大学犹太人健康。科罗拉多州医院，儿童医院，丹佛卫生系统，科罗拉多州的凯撒（Kaiser Permanente）和丹佛退伍军人管理局医疗中心。自2005年以来，该财团机构已承诺对癌症医学约1.01亿美元。有248个正式成员（几乎所有由NIH资助的科罗拉多州的癌症研究人员）参加了六项研究计划，包括：癌症细胞生物学；分子肿瘤学；发育治疗学；与激素相关的恶性肿瘤；肺部，头颈癌以及癌症预防和控制。在过去的五年中，与同行评审的癌症相关资金达到了1.02亿美元，并生产了3,181个出版物（35％的合作）。我们的研究创新在我们的成员在肺癌孢子，Livestrong卓越中心，生物标志物开发中心（ALK重排，EGFR，EGFR）中的铅角色举例说明，我们的病理学共享资源和顶级动物癌症中心的发展。年度对治疗试验的年度应计算从595增加到1,044，占新诊断的患者的27％。研究得到了整个财团的13个共享资源的支持，所有UCCC成员都可以访问。这些资源在我们的科罗拉多州临床和转化科学研究所（CCTSI）中利用NIH投资来通过避免重复和增强临界质量来提供成本效率。专注于战略招聘的发展活动，飞行员和种子赠款计划导致了直接癌症研究赠款资金的1100万美元投资回报率。在接下来的五年中，我们的战略计划包括开发转移和肿瘤微环境，癌症干细胞，生存和健康差异的计划，以及人类研究成像共享资源，该资源将跨越物种并增强我们的药物开发管道和个性化治疗临床试验。建筑中的其他临床和研究设施将使我们能够使我们的上升研究和临床生长轨迹。